Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications

Changes of flavin-containing monooxygenases and trimethylamine-N-oxide may be involved in the promotion of non-alcoholic fatty liver disease by intestinal microbiota metabolite trimethylamine

(2022) Chunxia Shi et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Effects of endoplasmic reticulum stress, liver function, insulin resistance and vascular endothelial function in patients with nonalcoholic fatty liver disease

(2022) Yong Zheng et al.   CELLULAR AND MOLECULAR BIOLOGY

TNF in the liver: targeting a central player in inflammation

(2022) Gisa Tiegs et al.   Seminars in Immunopathology

Relationship between hepatic gene expression, intestinal microbiota and inferred functional metagenomic analysis in NAFLD

(2022) Paulina Pettinelli et al.   Clinical and Translational Gastroenterology

Demonstration of gut-barrier dysfunction in early stages of non-alcoholic fatty liver disease: A proof-of-concept study

(2022) Kanav Kaushal et al.   Journal of Clinical and Experimental Hepatology

American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings

(2022) Kenneth Cusi et al.   Endocrine Practice

Dynamic microbiome and metabolome analyses reveal the interaction between gut microbiota and anti‐PD ‐1 based immunotherapy in hepatocellular carcinoma

(2022) Hewei Wu et al.   INTERNATIONAL JOURNAL OF CANCER

Antrodia cinnamomea and its compound dehydroeburicoic acid attenuate nonalcoholic fatty liver disease by upregulating ALDH2 activity

(2022) Yi-ni Cao et al.   JOURNAL OF ETHNOPHARMACOLOGY

Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1

(2022) John A. McCulloch et al.   NATURE MEDICINE

Neutrophil extracellular traps enriched with IL-1β and IL-17A participate in the hepatic inflammatory process of patients with non-alcoholic steatohepatitis

(2022) Stella Arelaki et al.   VIRCHOWS ARCHIV

Interleukin-17 Weakens the NAFLD/NASH Process by Facilitating Intestinal Barrier Restoration Depending on the Gut Microbiota

(2022) Shuying He et al.   mBio

A randomized controlled trial for response of microbiome network to exercise and diet intervention in patients with nonalcoholic fatty liver disease

(2022) Runtan Cheng et al.   Nature Communications

Lacticaseibacillus paracasei sh2020 induced antitumor immunity and synergized with anti-programmed cell death 1 to reduce tumor burden in mice

(2022) Shi-Long Zhang et al.   Gut Microbes

Effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction-associated fatty liver disease: Directed acyclic graphs

(2022) Saori Takamura et al.   Clinical and Molecular Hepatology

Role of Vitamin D in Liver Disease and Complications of Advanced Chronic Liver Disease

(2022) Federico Ravaioli et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Ecological memory of prior nutrient exposure in the human gut microbiome

(2022) Jeffrey Letourneau et al.   ISME Journal

Recent advances on FXR-targeting therapeutics

(2022) Katrin Panzitt et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Risk assessment with gut microbiome and metabolite markers in NAFLD development

(2022) Howell Leung et al.   Science Translational Medicine

Enterohepatic Takeda G-Protein Coupled Receptor 5 Agonism in Metabolic Dysfunction-Associated Fatty Liver Disease and Related Glucose Dysmetabolism

(2022) Justine Gillard et al.   Nutrients

Amelioration of Non-Alcoholic Steatohepatitis by Atractylodes macrocephala Polysaccharide, Chlorogenic Acid, and Geniposide Combination Is Associated With Reducing Endotoxin Gut Leakage

(2022) Jing Leng et al.   Frontiers in Cellular and Infection Microbiology

Effect of Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial

(2022) Lanfeng Xue et al.   Frontiers in Cellular and Infection Microbiology

Beneficial effects of UDCA and norUDCA in a rodent model of steatosis are linked to modulation of GPBAR1/FXR signaling

(2022) Silvia Marchianò et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS

CREBH alleviates mitochondrial oxidative stress through SIRT3 mediating deacetylation of MnSOD and suppression of Nlrp3 inflammasome in NASH

(2022) Junli Zhang et al.   FREE RADICAL BIOLOGY AND MEDICINE

Metformin, pioglitazone, dapagliflozin and their combinations ameliorate manifestations associated with NAFLD in rats via anti-inflammatory, anti-fibrotic, anti-oxidant and anti-apoptotic mechanisms

(2022) Hager H. Shaaban et al.   LIFE SCIENCES

Chemotactic cytokines secreted from Kupffer cells contribute to the sex-dependent susceptibility to non-alcoholic fatty liver diseases in mice

(2022) Yong-Hyun Han et al.   LIFE SCIENCES

Bacteriophage-antibiotic combination therapy against extensively drug-resistant Pseudomonas aeruginosa infection to allow liver transplantation in a toddler

(2022) Brieuc Van Nieuwenhuyse et al.   Nature Communications

Schisantherin A alleviates non-alcoholic fatty liver disease by restoring intestinal barrier function

(2022) Shenglan Yu et al.   Frontiers in Cellular and Infection Microbiology

Exercise inhibits JNK pathway activation and lipotoxicity via macrophage migration inhibitory factor in nonalcoholic fatty liver disease

(2022) Ni Cui et al.   Frontiers in Endocrinology

Phage therapy for pulmonary infections: lessons from clinical experiences and key considerations

(2022) Georgia Mitropoulou et al.   European Respiratory Review

Recent advances in the therapeutic application of short-chain fatty acids (SCFAs): An updated review

(2021) Abdur Rauf et al.   CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION

Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients

(2021) Diwakar Davar et al.   SCIENCE

A randomised placebo controlled trial of VSL#3® probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease

(2021) Pui Lin Chong et al.   BMC GASTROENTEROLOGY

Nonalcoholic Fatty Liver Disease: A Global Perspective

(2021) Wei-Kei Wong et al.   CLINICAL THERAPEUTICS

Nonalcoholic Fatty Liver Disease: Focus on New Biomarkers and Lifestyle Interventions

(2021) Maria Notarnicola et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Effects of lifestyle interventions on epigenetic signatures of liver fat: CENTRAL randomized controlled trial

(2021) Anat Yaskolka Meir et al.   LIVER INTERNATIONAL

Berberine attenuates choline-induced atherosclerosis by inhibiting trimethylamine and trimethylamine-N-oxide production via manipulating the gut microbiome

(2021) Xingxing Li et al.   npj Biofilms and Microbiomes

Interleukin-17-Producing CD4+ T Cells Promote Inflammatory Response and Foster Disease Progression in Hyperlipidemic Patients and Atherosclerotic Mice

(2021) Yin Wang et al.   Frontiers in Cardiovascular Medicine

Novel approaches to intervene gut microbiota in the treatment of chronic liver diseases

(2021) Chang Liu et al.   FASEB JOURNAL

Altered profiles of fecal bile acids correlate with gut microbiota and inflammatory responses in patients with ulcerative colitis

(2021) Zhen-Huan Yang et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Gut microbiome-mediated metabolism effects on immunity in rural and urban African populations

(2021) Martin Stražar et al.   Nature Communications

Potential Benefits of Probiotics and Prebiotics for Coronary Heart Disease and Stroke

(2021) Haicui Wu et al.   Nutrients

The Effect of Probiotics (MCP® BCMC® Strains) on Hepatic Steatosis, Small Intestinal Mucosal Immune Function, and Intestinal Barrier in Patients with Non-Alcoholic Fatty Liver Disease

(2021) Mohamad Hizami Mohamad Nor et al.   Nutrients

A Multicenter, Randomized Phase III Study Comparing Platinum Combination Chemotherapy Plus Pembrolizumab With Platinum Combination Chemotherapy Plus Nivolumab and Ipilimumab for Treatment-Naive Advanced Non–Small Cell Lung Cancer Without Driver Gene Alterations: JCOG2007 (NIPPON Study)

(2021) Yoshimasa Shiraishi et al.   Clinical Lung Cancer

The Role of Gut-Derived Lipopolysaccharides and the Intestinal Barrier in Fatty Liver Diseases

(2021) Lingxuan An et al.   JOURNAL OF GASTROINTESTINAL SURGERY

Intestine-liver crosstalk in Type 2 Diabetes and non-alcoholic fatty liver disease

(2021) Margaux Nawrot et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Adjunctive Probiotic Lactobacillus rhamnosus Probio-M9 Administration Enhances the Effect of Anti-PD-1 Antitumor Therapy via Restoring Antibiotic-Disrupted Gut Microbiota

(2021) Guangqi Gao et al.   Frontiers in Immunology

Statins in Non-alcoholic Steatohepatitis

(2021) Jose D. Torres-Peña et al.   Frontiers in Cardiovascular Medicine

The Effects of Pathogen-Associated Molecular Patterns on Peripheral Blood Monocytes in Patients with Non-alcoholic Fatty Liver Disease

(2021) Qian Li et al.   Journal of Clinical and Experimental Hepatology

Response to PD-1-Based Immunotherapy for Non-Small Cell Lung Cancer Altered by Gut Microbiota

(2021) Daqiang He et al.   Oncology and Therapy

EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study

(2021) Vlad Ratziu et al.   JOURNAL OF HEPATOLOGY

Fecal Microbiota Transplantation for Chronic Liver Diseases: Current Understanding and Future Direction

(2020) Sarah Lechner et al.   DIGESTIVE DISEASES AND SCIENCES

Synbiotic Alters Fecal Microbiomes, but not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Non-alcoholic Fatty Liver Disease

(2020) Eleonora Scorletti et al.   GASTROENTEROLOGY

Epidemiological feature of NAFLD from 1999 to 2018 in China

(2020) Jianghua Zhou et al.   HEPATOLOGY

Cilofexor, a Nonsteroidal FXR Agonist, in Non‐Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial

(2020) Keyur Patel et al.   HEPATOLOGY

Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis

(2020) Donatella Chianelli et al.   JOURNAL OF MEDICINAL CHEMISTRY

Serum Fibroblast Growth Factor 19 and Total Bile Acid Concentrations Are Potential Biomarkers of Hepatocellular Carcinoma in Patients with Type 2 Diabetes Mellitus

(2020) Yi Sun et al.   Biomed Research International

Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study

(2020) Harry Sokol et al.   Microbiome

Allogenic Fecal Microbiota Transplantation in Patients With Nonalcoholic Fatty Liver Disease Improves Abnormal Small Intestinal Permeability

(2020) Laura Craven et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Advanced liver steatosis accompanies an increase in hepatic inflammation, colonic, secondary bile acids and Lactobacillaceae/Lachnospiraceae bacteria in C57BL/6 mice fed a high-fat diet

(2020) Huawei Zeng et al.   JOURNAL OF NUTRITIONAL BIOCHEMISTRY

Contribution of endotoxin to Th17 bias in patients with non-alcoholic steatohepatitis

(2020) Xu Wang et al.   MICROBIAL PATHOGENESIS

The gut microbiome modulates gut–brain axis glycerophospholipid metabolism in a region-specific manner in a nonhuman primate model of depression

(2020) Peng Zheng et al.   MOLECULAR PSYCHIATRY

A Universal Gut-Microbiome-Derived Signature Predicts Cirrhosis

(2020) Tae Gyu Oh et al.   Cell Metabolism

FXR Isoforms Control Different Metabolic Functions in Liver Cells via Binding to Specific DNA Motifs

(2020) Jose Miguel Ramos Pittol et al.   GASTROENTEROLOGY

Ileal bile acid transporter inhibition as an anticholestatic therapeutic target in biliary atresia and other cholestatic disorders

(2020) Saul J. Karpen et al.   Hepatology International

Prolonged Lipid Accumulation in Cultured Primary Human Hepatocytes Rather Leads to ER Stress than Oxidative Stress

(2020) Christiane Rennert et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Effects of probiotic and prebiotic supplementation on metabolic parameters, liver aminotransferases, and systemic inflammation in nonalcoholic fatty liver disease: A randomized clinical trial

(2020) Vahideh Behrouz et al.   JOURNAL OF FOOD SCIENCE

Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD

(2020) Giljae Lee et al.   Nature Communications

Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease

(2020) Takaomi Kessoku et al.   BMJ Open

Metabolic Functions of G Protein-Coupled Receptors in Hepatocytes—Potential Applications for Diabetes and NAFLD

(2020) Takefumi Kimura et al.   Biomolecules

Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients

(2020) Erez N. Baruch et al.   SCIENCE

Effect of Fecal Microbiota Transplantation on 8-Week Remission in Patients With Ulcerative Colitis

(2019) Samuel P. Costello et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The Role of Probiotics and Prebiotics in the Prevention and Treatment of Obesity

(2019) Tomás Cerdó et al.   Nutrients

Gut microbiome–targeted therapies in nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression

(2019) Suzanne R Sharpton et al.   AMERICAN JOURNAL OF CLINICAL NUTRITION

Trimethylamine N ‐Oxide Aggravates Liver Steatosis through Modulation of Bile Acid Metabolism and Inhibition of Farnesoid X Receptor Signaling in Nonalcoholic Fatty Liver Disease

(2019) Xuying Tan et al.   MOLECULAR NUTRITION & FOOD RESEARCH

Randomized, Double-blind, Placebo-controlled Study of a Multispecies Probiotic Mixture in Nonalcoholic Fatty Liver Disease

(2019) Sang Bong Ahn et al.   Scientific Reports

Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease

(2019) Rohit Loomba et al.   Cell Metabolism

Acanthoic acid modulates lipogenesis in nonalcoholic fatty liver disease via FXR/LXRs-dependent manner

(2019) Xin Han et al.   CHEMICO-BIOLOGICAL INTERACTIONS

Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development

(2019) Juliette Mouries et al.   JOURNAL OF HEPATOLOGY

CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients

(2019) Paul J. Pockros et al.   LIVER INTERNATIONAL

Fatty Liver Disease Caused by High-Alcohol-Producing Klebsiella pneumoniae

(2019) Jing Yuan et al.   Cell Metabolism

Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease

(2019) Yi Duan et al.   NATURE

High-fat diet-mediated dysbiosis exacerbates NSAID-induced small intestinal damage through the induction of interleukin-17A

(2019) Naoki Sugimura et al.   Scientific Reports

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

(2019) Zobair M Younossi et al.   LANCET

Link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD

(2018) Cyrielle Caussy et al.   HEPATOLOGY

Gut microbiome–mediated bile acid metabolism regulates liver cancer via NKT cells

(2018) Chi Ma et al.   SCIENCE

A novel ASBT inhibitor, IMB17-15, repressed nonalcoholic fatty liver disease development in high-fat diet-fed Syrian golden hamsters

(2018) Mao-xu Ge et al.   ACTA PHARMACOLOGICA SINICA

Dysregulated Microbial Fermentation of Soluble Fiber Induces Cholestatic Liver Cancer

(2018) Vishal Singh et al.   CELL

TGR5 Activation Promotes Stimulus-Secretion Coupling of Pancreatic β-Cells via a PKA-Dependent Pathway

(2018) Jonas Maczewsky et al.   DIABETES

Interleukin-17/interleukin-17 receptor axis elicits intestinal neutrophil migration, restrains gut dysbiosis and lipopolysaccharide translocation in high-fat diet-induced metabolic syndrome model

(2018) Malena M. Pérez et al.   IMMUNOLOGY

IL-17A-mediated ERK1/2/p65 Signaling Pathway is Associated with Cell Apoptosis after Non-alcoholic Steatohepatitis

(2018) Ya-jie Pan et al.   IUBMB LIFE

Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD

(2017) Na Jiao et al.   GUT

Targeting the gut-liver axis in liver disease

(2017) Reiner Wiest et al.   JOURNAL OF HEPATOLOGY

Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota

(2017) Da Zhou et al.   Scientific Reports

Colonic infusions of short-chain fatty acid mixtures promote energy metabolism in overweight/obese men: a randomized crossover trial

(2017) Emanuel E. Canfora et al.   Scientific Reports

Bile acids induce uncoupling protein 1-dependent thermogenesis and stimulate energy expenditure at thermoneutrality in mice

(2016) Marika Zietak et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Bile acid receptor agonists INT747 and INT777 decrease oestrogen deficiency-related postmenopausal obesity and hepatic steatosis in mice

(2016) Monique C. de Oliveira et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach

(2016) Federica Del Chierico et al.   HEPATOLOGY

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes

(2016) Zobair M. Younossi et al.   HEPATOLOGY

Promotion of Intestinal Epithelial Cell Turnover by Commensal Bacteria: Role of Short-Chain Fatty Acids

(2016) Jung-ha Park et al.   PLoS One

Short Chain Fatty Acids Prevent High-fat-diet-induced Obesity in Mice by Regulating G Protein-coupled Receptors and Gut Microbiota

(2016) Yuanyuan Lu et al.   Scientific Reports

Effects of Multistrain Probiotic Supplementation on Glycemic and Inflammatory Indices in Patients with Nonalcoholic Fatty Liver Disease: A Double-Blind Randomized Clinical Trial

(2015) Abbaszadeh Sepideh et al.   JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

(2015) Brent A Neuschwander-Tetri et al.   LANCET

Nonalcoholic fatty liver disease

(2015) Elizabeth M. Brunt et al.   Nature Reviews Disease Primers

Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis

(2014) A. Alisi et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Is serum Interleukin-17 associated with early atherosclerosis in obese patients?

(2014) Giovanni Tarantino et al.   Journal of Translational Medicine

Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

(2013) Sunder Mudaliar et al.   GASTROENTEROLOGY

Bile Acid Receptor Activation Modulates Hepatic Monocyte Activity and Improves Nonalcoholic Fatty Liver Disease

(2013) Rachel H. McMahan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Choline intake in a large cohort of patients with nonalcoholic fatty liver disease

(2012) Anthony L Guerrerio et al.   AMERICAN JOURNAL OF CLINICAL NUTRITION

Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: A randomized controlled trial

(2012) Thuy-Anh Le et al.   HEPATOLOGY

Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease

(2010) Zhao-Xia Yang et al.   Hepatology International